Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Antiretroviral Therapy (OAT)
NCT02935075Phase 4Completed
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate and efavirenz in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoint: Percentage of patients with HIV viral load < 50 copies/ml at 48 weeks. Started Mar 2018; status: completed.
02
Drugs
tenofovir disoproxil fumarateefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02935075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02935075.